HEMBROUGH, TODD,CECCHI, FABIOLA,SCHWARTZ, SARIT,YAU, CHRISTINA
申请号：
CA3065333
公开号：
CA3065333A1
申请日:
2018.06.04
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Methods are provided for identifying whether a cancer patient, and especiallya gastric cancer patient, will be responsiveto treatment with a sequential therapeutic strategy comprising a firstadministration of the FOLFIRI regimen (irinotecan/5-fluoruracil/folinic acid)followed by a separate sequential administration of the combination of thechemotherapy agents docetaxel andcisplatin (FOLFIRI + docetaxel/cisplatin). Specified TUBB3 and TYMP fragmentpeptides are precisely detected and quantitated bySRM-mass spectrometry directly in tumor cells, and especially gastric cancertumor cells, that are collected from tumor tissue obtainedfrom a cancer patient and compared to reference levels in order to determineif the cancer patients will positively respond to treatmentwith the sequential combination treatment of FOLFIRI + docetaxel/cisplatin.
